AB Biosciences
Masazumi Nagai is a seasoned scientist in the field of biochemistry and dentistry, currently serving as Principal Lead Scientist at Northway Biotech since October 2022 and as a Senior Investigator at AB Biosciences since April 2022. Masazumi Nagai has held multiple academic roles, including Visiting Professor at Iwate Medical University and Lecturer in Oral Medicine Infection and Immunity at Harvard School of Dental Medicine. Additionally, previous positions include Principal Scientist at Northway Biotech, Senior Scientist at QLB Biotherapeutics, and Scientist at Abpro Therapeutics. Masazumi Nagai's extensive experience in the pharmaceutical and biotechnology industries began in 2003 at Synta Pharmaceuticals. The academic background includes a Doctor of Philosophy (Ph.D.) in Dentistry/Biochemistry from Harvard School of Dental Medicine and undergraduate studies at Iwate Medical University.
This person is not in the org chart
This person is not in any teams
AB Biosciences
Our Mission To create best niche antibody-based biologics for fulfilling the research and development needs in biomedical and biopharmaceutical communities. Our long range goal is to develop therapeutic and diagnostic entities. Core Competence ABB’s core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools. History Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABB’s scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG. Our Community Massachusetts provides a vibrant and nurturing environment for life science ventures like ABB, in terms of training grants and tax benefits, as well as an abundant talent pool possessing a wide range of expertise. Discovering breakthrough biotechnology and exploring biologics for biomedical study is our mission at AB Biosciences. As part of our commitment to science education, we open our doors to intern students, who can experience firsthand the R&D employment possibilities in the Biotech Industry. More than 15 students/interns have visited our laboratory since 2009.